Answers are grounded in this paper and cite their sources.
One of the key ways to translate new basic discoveries into clinical relevance is the analysis of gene expression in tumour samples, relating this to various outcomes. These may include relapse-free survival and overall survival, sites of metastasis and, of course, differential expression in tumour vs normal is important to describe. The above are prognostic factors, but use of markers to predict which patients will benefit from increasingly complex and expensive therapies is potentially of high utility and a logical follow on, once patients with poor prognosis are selected. To achieve the goal of individualised medicine, with the selection of correct therapy for the molecular pathways in the tumour, this approach is needed.
No takes yet. Share an insight, caveat, or question.
Adrian L. Harris (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: